Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia.
Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur-Royal College of Medicine Perak, Ipoh 30450, Perak, Malaysia.
Molecules. 2021 Nov 9;26(22):6768. doi: 10.3390/molecules26226768.
Approximately 100-400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific dengue inhibitors is expanding, and the mechanisms for evaluating the efficacy of novel drugs are currently established, allowing for expedited translation into human trials. Furthermore, in the aftermath of the only FDA-approved vaccine, Dengvaxia, a safer and more effective dengue vaccine candidate is making its way through the clinical trials. Until an effective antiviral therapy and licensed vaccine are available, disease monitoring and vector population control will be the mainstays of dengue prevention. In this article, we highlighted recent advances made in the perspectives of efforts made recently, in dengue vaccine development and dengue antiviral drug.
全球 100 多个热带和亚热带国家约有 1 亿至 4 亿人受到登革热感染。最近的科学突破为生产登革热抗病毒药物和疫苗带来了新的策略。寻找特定的登革热抑制剂的工作正在扩大，评估新型药物疗效的机制也已经建立，这使得它们能够更快地转化为人体试验。此外，在唯一获得 FDA 批准的疫苗 Dengvaxia 之后，一种更安全、更有效的登革热候选疫苗正在进行临床试验。在获得有效的抗病毒疗法和许可疫苗之前，疾病监测和病媒种群控制将是登革热预防的主要手段。在本文中，我们强调了最近在登革热疫苗开发和登革热抗病毒药物方面所做努力的最新进展。
